HHS draft policy does not intend to act against compounding six peptides that meet strict conditions

Tento záznam se zobrazuje v angličtině, dokud nebude aktualizován jeho překlad.

The US Department of Health and Human Services announced a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157, epitalon, KPV, MOTS-c, semax or TB-500 while the FDA's 503A bulk substances list is developed through rulemaking, but only when every condition in the policy is met. Those conditions include using only the peptide form and route of administration the policy lists, one active ingredient per product, a patient-specific prescription, a raw ingredient made by an FDA-registered manufacturer following good manufacturing practice with a valid certificate of analysis (lab test report), and reporting serious adverse events to the FDA. The notice, published in the Federal Register on 30 October with written comments accepted for two weeks, says the policy is not binding and may be revisited if a safety signal or product quality issue arises. It does not approve these peptides or add them to the list, and compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before they are marketed.

Zdroje

  1. 01Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances(otevře zdroj na nové kartě) Federal Register
  2. 02Draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances(otevře zdroj na nové kartě) US Department of Health and Human Services
  3. 03HHS to allow compounders to make 6 unapproved peptides(otevře zdroj na nové kartě) BioPharma Dive
  4. 04HHS Announces Draft Enforcement Discretion Policy Paving Way for Pharmacies to Compound Certain Peptides While FDA Rulemaking Is Pending(otevře zdroj na nové kartě) Arnold & Porter

Dotčené peptidy

  1. NeschválenoBPC-157Syntetický žaludeční pentadekapeptid (výzkumná chemikálie)15 Zakázáno WADA
  2. NeschválenoEpitalonSyntetický tetrapeptid ze šišinky (kandidát na geroprotektor)4 Zakázáno WADA
  3. NeschválenoKPVTripeptid odvozený od alfa-MSH (výzkumná chemikálie)3 Zakázáno WADA
  4. NeschválenoMOTS-cPeptid odvozený z mitochondrií (výzkumný peptid)16 Zakázáno WADA
  5. Schváleno jindeSemaxAnalog fragmentu ACTH(4-10) (neuropeptid odvozený od melanokortinů)7
  6. NeschválenoTB-500Fragment thymosinu beta-4 (výzkumná chemikálie)7 Zakázáno WADA